These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27322462)

  • 1. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.
    Kim J; Davis JW; Klein EA; Magi-Galluzzi C; Lotan Y; Ward JF; Pisters LL; Basler JW; Pettaway CA; Stephenson A; Li Ning Tapia EM; Efstathiou E; Wang X; Do KA; Lee JJ; Gorlov IP; Vornik LA; Hoque AM; Prokhorova IN; Parnes HL; Lippman SM; Thompson IM; Brown PH; Logothetis CJ; Troncoso P
    EBioMedicine; 2016 May; 7():85-93. PubMed ID: 27322462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
    Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
    J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
    Lucia MS; Epstein JI; Goodman PJ; Darke AK; Reuter VE; Civantos F; Tangen CM; Parnes HL; Lippman SM; La Rosa FG; Kattan MW; Crawford ED; Ford LG; Coltman CA; Thompson IM
    J Natl Cancer Inst; 2007 Sep; 99(18):1375-83. PubMed ID: 17848673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
    Wu WF; Wang L; Spetsieris N; Boukovala M; Efstathiou E; Brössner C; Warner M; Gustafsson JA
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33771918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
    Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
    Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.
    Hernandez J; Gelfond J; Goros M; Liss MA; Liang Y; Ankerst D; Thompson IM; Leach RJ
    PLoS One; 2018; 13(10):e0204823. PubMed ID: 30300367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.
    Hoque A; Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; vanBokhoven A; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Ambrosone CB; Thompson IM
    Urology; 2015 Mar; 85(3):616-20. PubMed ID: 25733274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
    Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
    Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.
    Dai JY; LeBlanc M; Goodman PJ; Lucia MS; Thompson IM; Tangen CM
    Cancer Prev Res (Phila); 2019 Feb; 12(2):113-120. PubMed ID: 30538099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
    Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
    Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intriguing role of fibroblasts and
    Niu YN; Wang K; Jin S; Fan DD; Wang MS; Xing NZ; Xia SJ
    Asian J Androl; 2016; 18(6):913-919. PubMed ID: 26698232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of prostate cancer with finasteride: US/European perspective.
    Thompson IM; Klein EA; Lippman SM; Coltman CA; Djavan B
    Eur Urol; 2003 Dec; 44(6):650-5. PubMed ID: 14644115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of High Androgen Receptor Expression in Prostatic Acinar Adenocarcinoma.
    Hashmi AA; Mudassir G; Irfan M; Hussain ZF; Hashmi SK; Asif H; Nisar L; Naeem M; Faridi N
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):893-896. PubMed ID: 30912411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.